Abstract
Sepsis associated Acute Kidney Injury (SA-AKI) is the leading cause of AKI in the hospital setting and its incidence is increasing. Although the exact pathophysiology and phenotype of SA-AKI are not known, it is widely accepted that SA-AKI has a multi-injury pathway. This form of AKI has components of ischemia-reperfusion injury, direct inflammatory injury, coagulation and endothelial cell dysfunction, and apoptosis. As such, multiple agents have been shown in pre-clinical studies to ameliorate SA-AKI, but there are no interventions currently available for the treatment of SA-AKI. Promising agents that are in development include toll-like receptor inhibition, IL-10 augmentation, modulators of the protein C pathway, and mesenchymal stem cell mediated therapeutics. The aim of this review is to review the pathophysiology of SA-AKI and the therapeutic interventions that are under development to treat this complex and morbid disease.
Keywords: Sepsis associated acute kidney injury, inflammation, IL-6, toll-like receptors, IL-10, ischemia reperfusion injury, apoptosis, activated protein C, soluble thrombomodulin, ethyl pyruvate
Current Drug Targets
Title: Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury
Volume: 10 Issue: 12
Author(s): Christian H. Pelte and Lakhmir S. Chawla
Affiliation:
Keywords: Sepsis associated acute kidney injury, inflammation, IL-6, toll-like receptors, IL-10, ischemia reperfusion injury, apoptosis, activated protein C, soluble thrombomodulin, ethyl pyruvate
Abstract: Sepsis associated Acute Kidney Injury (SA-AKI) is the leading cause of AKI in the hospital setting and its incidence is increasing. Although the exact pathophysiology and phenotype of SA-AKI are not known, it is widely accepted that SA-AKI has a multi-injury pathway. This form of AKI has components of ischemia-reperfusion injury, direct inflammatory injury, coagulation and endothelial cell dysfunction, and apoptosis. As such, multiple agents have been shown in pre-clinical studies to ameliorate SA-AKI, but there are no interventions currently available for the treatment of SA-AKI. Promising agents that are in development include toll-like receptor inhibition, IL-10 augmentation, modulators of the protein C pathway, and mesenchymal stem cell mediated therapeutics. The aim of this review is to review the pathophysiology of SA-AKI and the therapeutic interventions that are under development to treat this complex and morbid disease.
Export Options
About this article
Cite this article as:
Pelte H. Christian and Chawla S. Lakhmir, Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury, Current Drug Targets 2009; 10 (12) . https://dx.doi.org/10.2174/138945009789753219
DOI https://dx.doi.org/10.2174/138945009789753219 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use
Cardiovascular & Hematological Disorders-Drug Targets Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Update Clinical Application of Diffusion Tensor Imaging
Current Medical Imaging Cell-based Treatment of Cerebral Palsy: Still a Long Way Ahead
Current Stem Cell Research & Therapy Metabolic Stress and Inflammation: Implication in Treatment for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Equol is Neuroprotective During Focal Cerebral Ischemia and Reperfusion that Involves p-Src and gp91<sup>phox</sup>
Current Neurovascular Research Wound Healing Effects of Curcumin: A Short Review
Current Pharmaceutical Biotechnology Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design Immunomodulatory Properties of Farnesoids: The New Steroids?
Current Medicinal Chemistry Oral Administration of the Food-Derived Hydrophilic Antioxidant Ergothioneine Enhances Object Recognition Memory in Mice
Current Molecular Pharmacology Pharmacological Modulation of Caspase Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Atherosclerosis Time-Line and the Role of the Endothelium
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents A Review of Systemic Vasodilators in Low Cardiac Output Syndrome Following Pediatric Cardiac Surgery
Current Vascular Pharmacology Aesthetic Cardiology: Adipose-Derived Stem Cells for Myocardial Repair
Current Stem Cell Research & Therapy May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?
Cardiovascular & Hematological Disorders-Drug Targets Adrenomedullin in Heart Failure: Molecular Mechanism and Therapeutic Implication
Current Hypertension Reviews Pharmacogenetics, Pharmacogenomics and Epigenetics of Nrf2-regulated Xenobioticmetabolizing Enzymes and Transporters by Dietary Phytochemical and Cancer Chemoprevention
Current Drug Metabolism Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews